Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Lyell Immunopharma, Inc. (LYEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 85.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-12
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 75.90%, a 17.41% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 91.90%, a 7.86% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 85.20%, a 6.50% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 80.00%.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 85.70%, a 12.91% increase from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 75.90%, a 13.75% decline from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 88.00%, a 0.80% increase from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 87.30%, a 10.93% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 85.70% 10-K · filed 2026-03-12 | |||||||
| 2024-12-31 | 75.90% 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | 76.00% 10-Q · filed 2024-11-07 | |||||||
| 2024-06-30 | 76.00% 10-Q · filed 2024-08-07 | |||||||
| 2024-03-31 | 75.90% 10-Q · filed 2024-05-06 | |||||||
| 2023-12-31 | 88.00% 10-K · filed 2026-03-12 | |||||||
| 2023-09-30 | 88.20% 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | 92.40% 10-Q · filed 2024-08-07 | |||||||
| 2023-03-31 | 91.90% 10-Q · filed 2024-05-06 | |||||||
| 2022-12-31 | 87.30% 10-K · filed 2025-03-11 | |||||||
| 2022-09-30 | 85.60% 10-Q · filed 2023-11-07 | |||||||
| 2022-06-30 | 85.50% 10-Q · filed 2023-08-08 | 85.00% 10-Q · filed 2022-08-04 | ||||||
| 2022-03-31 | 85.20% 10-Q · filed 2023-05-04 | 85.00% 10-Q · filed 2022-05-10 | ||||||
| 2021-12-31 | 78.70% 10-K · filed 2024-02-28 | 79.00% 10-K · filed 2022-03-29 | ||||||
| 2021-09-30 | 78.70% 10-Q · filed 2022-11-08 | 79.00% 10-Q · filed 2021-11-12 | ||||||
| 2021-06-30 | 79.00% 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | 80.00% 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 75.00% 10-K · filed 2023-02-28 | |||||||
| 2020-09-30 | 75.00% 10-Q · filed 2021-11-12 | |||||||
| 2020-06-30 | 75.00% 10-Q · filed 2021-08-12 | |||||||
| 2019-12-31 | 75.00% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |